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Background: HIV-1 replication can be successfully blocked by targeting gag gene products, offering a promising
strategy for new drug classes that complement current HIV-1 treatment options. However, naturally occurring
polymorphisms at drug binding sites can severely compromise HIV-1 susceptibility to gag inhibitors in clinical and
experimental studies. Therefore, a comprehensive understanding of gag natural diversity is needed.
Findings: We analyzed the degree of functional conservation in 10862 full-length gag sequences across 8 major HIV-1
subtypes and identified the impact of natural variation on known drug binding positions targeted by more than 20
gag inhibitors published to date. Complete conservation across all subtypes was detected in 147 (29%) out of 500
gag positions, with the highest level of conservation observed in capsid protein. Almost half (41%) of the 136 known
drug binding positions were completely conserved, but all inhibitors were confronted with naturally occurring
polymorphisms in their binding sites, some of which correlated with HIV-1 subtype. Integration of sequence and
structural information revealed one drug binding pocket with minimal genetic variability, which is situated at the
N-terminal domain of the capsid protein.
Conclusions: This first large-scale analysis of full-length HIV-1 gag provided a detailed mapping of natural diversity
across major subtypes and highlighted the considerable variation in current drug binding sites. Our results contribute
to the optimization of gag inhibitors in rational drug design, given that drug binding sites should ideally be conserved
across all HIV-1 subtypes.
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acid conservationIntroduction
A curative therapy or preventive vaccine for HIV-1 infected
patients remains elusive to date. Standard HIV treatment is
confronted with the emergence of viral resistance to exist-
ing drug classes, necessitating the development of inhibi-
tors with new mechanisms of action [1]. The gag
polyprotein, essential for HIV-1 morphogenesis, comprises
four major domains (matrix, capsid, nucleocapsid, p6) and
two small spacer peptides (p1, p2) [2]. Recently, HIV-1 in-
hibitors that target different stages of virion morphogenesis
demonstrated promising antiviral activity, mainly by inhi-
biting capsid assembly, disrupting nucleocapsid binding
with viral RNA/DNA or blocking proteolytic processing of
polyproteins during maturation [2-5].* Correspondence: Kristof.Theys@rega.kuleuven.be
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reproduction in any medium, provided the orHIV-1 subtype B isolates were predominantly used for
the in vitro experiments. Non-B subtypes however ac-
count for 90% of HIV-1 infections worldwide [6] and
amino acid (AA) compositions can differ up to 30% be-
tween subtypes [7]. Recently, treatment failure of pa-
tients in a phase II clinical study of the maturation
inhibitor bevirimat was attributed to natural polymor-
phisms at drug binding positions, showing up in
subtype-specific patterns [8]. Studies that extensively in-
vestigate the implications of HIV-1 diversity for gag-
directed drug development are lacking to date. In this
large-scale analysis, we examined the distribution of nat-
urally occurring sequence variability in full-length gag
sequences of major HIV-1 subtypes. Moreover, we evalu-
ated the impact of HIV-1 subtypes on the conservation
of gag drug binding positions and multisite binding
pockets published to date.his is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Figure 1 Distribution of natural variations at 500 gag positions of HIV-1 group M (subtypes: A1, B, C, D, F1, G and CRF01_AE,
CRF02_AG). The first position of each protein region is labeled with its protein name in a box. Annotated protein regions are indicated as
colored bars: light-green for matrix (positions 1–132), light-blue for capsid (133–363), dark-green for p2 (364–377) and p1 (433–448), dark-blue for
nucleocapsid (378–432) and grey for p6 (449–500). HXB2 indices for both full-length gag and individual proteins are shown on top of the colored
bars (e.g. ‘180|48’ indicates the gag position 180 and the capsid position 48). Known drug binding positions are marked with red stars. Consensus
subtype B amino acid for each position is shown directly under the bar, and is highlighted green when the consensus AA differed in one or more
subtypes. Natural polymorphisms are shown below the consensus subtype B amino acids; proportions (%) are colored blue for proportion ≥ 5%;
orange otherwise. Figure S1 in Additional file 2 provides the distribution of natural polymorphisms within each individual subtype.
Table 1 Natural polymorphism proportions in gag domains and drug binding positions across 8 HIV-1 subtypes and
CRFs (%)
B A1 C D F1 G 01_AE 02_AG Mean
Matrix[132/13] 57.6/38.5 62.1/46.2 59.1/46.2 64.4/53.8 52.3/46.2 66.7/61.5 61.4/46.2 56.1/30.8 59.9/46.2
Capsid[231/98] 27.3/30.6 34.2/33.7 29.4/29.6 27.7/27.6 31.2/37.8 30.3/28.6 28.1/28.6 27.3/27.6 29.4/30.5
p2[14/8] 71.4/62.5 64.3/62.5 64.3/62.5 64.3/62.5 57.1/62.5 71.4/62.5 64.3/62.5 50.0/50.0 63.4/60.9
NC[55/17] 56.4/58.8 41.8/35.3 38.2/41.2 36.4/29.4 34.5/23.5 54.5/58.8 43.6/35.3 34.5/41.2 42.5/40.4
p1[16/0] 37.5/- 25.0/- 31.2/- 43.8/- 25.0/- 31.2/- 31.2/- 12.5/- 29.7/-
p6[52/0] 76.9/- 69.2/- 69.2/- 55.8/- 65.4/- 61.5/- 69.2/- 57.7/- 65.6/-
Mean 45.2/36.8 46.6/36.8 43.4/34.6 42.8/32.4 41.2/38.2 47.0/37.5 44.0/33.1 39.0/30.9 43.6/35.0
Each gag protein is demonstrated with its total AA and drug binding positions (e.g. Matrix [132/13]: 132 AA positions/13 drug binding positions). Natural
polymorphism proportion (%) is indicated for each protein and subtype with respect to the total number of AAs and to the number of drug binding positions
(e.g. 57.6/38.5 shows that for subtype B matrix, 57.6% of all 132 positions and 38.5% of 13 drug binding positions are polymorphic). Mean values across gag
domains and across HIV-1 subtypes are indicated in the last row and column respectively.
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Table 2 The inter- and intra-subtype diversity of gag AA sequences in 8 HIV-1 subtypes and CRFs (%)
Subtype B A1 C D F1 G 01_AE 02_AG
Intra-subtype 8.96 8.34 9.89 8.91 9.45 10.90 7.58 8.26
Inter-subtype B 17.54 18.38 12.70 16.52 18.46 17.22 18.61
A1 17.65 16.73 16.93 17.27 12.71 14.69
C 16.67 17.21 18.02 18.22 19.59
D 16.55 17.56 16.85 18.72
F1 15.93 16.48 17.68
G 17.70 18.81
01_AE 14.92
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We analyzed 10862 full-length gag sequences that ful-
filled the quality criteria, encompassing 8 HIV-1 group
M subtypes and CRFs: A1 (n = 1648), B (n = 4131), C
(n = 2780), D (n = 443), F1 (n = 35), G (n = 49),
CRF01_AE (n = 1714) and CRF02_AG (n = 62). Se-
quences were sampled from 61 countries between 1981
and 2012. Additional file 1: Table S1 summarizes more
than 50 gag inhibitors including their binding sites, tar-
get protein, mechanism of action, HIV-1 subtypes and
PDB data. These candidate inhibitors were either small
organic molecules or peptides and primarily targeted the
capsid or nucleocapsid proteins. A total of 136 gag posi-
tions were reported as drug binding positions, of which
53 interacted with more than one inhibitor.
The AA distribution at 500 gag positions among HIV-
1 group M sequences is shown in Figure 1 and subtype-
specific distributions are also visualized (Additional file 2:
Figure S1). Heterogeneity in consensus sequences was ob-
served at 142 (28.4%) positions across subtypes, while
pairwise comparisons of consensus sequences showed an
average of 11.6% difference between subtypes. On average,
43.6 ± 2.7% of positions harbored at least one polymorph-
ism relative to its subtype consensus residue (Table 1).
The capsid protein (29.4%) contained the lowest number
of polymorphic positions followed by nucleocapsid
(42.5%), matrix (59.9%), and p6 (65.6%). Moreover, of 147Table 3 The pairwise AA diversity of gag domains in 8 HIV-1
Matrix Capsid p2
B 12.36 4.56 20.65
A1 10.69 5.46 13.97
C 14.77 5.77 23.79
D 12.74 4.87 25.62
F1 12.71 5.37 29.24
G 17.51 6.15 16.06
01_AE 11.36 3.44 24.36
02_AG 13.67 4.91 18.50
Mean 13.17±2.01 5.04±0.79 21.49±4.83conserved positions in gag, 67.8% were in capsid, 11.2% in
nucleocapsid, 10.5% in matrix and 4.6% in p6. Pairwise
AA diversity (Additional file 3) of full-length gag
sequences decreased from 17.0 ± 1.6% between subtypes
to 9.0 ± 1.0% within subtypes (Table 2). The mean AA
diversity was significantly lower for capsid (5.0 ± 0.8%)
than for nucleocapsid (7.9 ± 2.8%), matrix (13.2 ± 2.0%) or
p6 (14.7 ± 2.0%) (p-value < 0.05) (Table 3). The CI distri-
butions of full-length gag characterized three conserved
regions located at the nucleocapsid zinc-finger domains,
the capsid N-terminal domain (NTD) and C-terminal
domain (CTD) (Figure 2).
Subtype-specific AA prevalence at the 136 drug bind-
ing positions is shown in Figure 3. Most positions were
located within capsid (72.1%) followed by nucleocapsid
(12.5%), matrix (9.6%) and p2 (5.9%). Of these positions,
41.2% were conserved across all subtypes, while 20.6%
showed a different consensus AA in one or more sub-
types. On average, 33.8% of drug binding positions har-
bored at least one polymorphism and 16.3% had at least
one polymorphism above 5% prevalence. Non-B sub-
types displayed 32 polymorphisms at 20 binding posi-
tions that were absent in subtype B. Every inhibitor had
at least one polymorphic binding position and 15 inhibi-
tors had more than 50% of drug binding positions show-
ing natural polymorphisms. Among all inhibitors,
PF-3450074 [9] targeted the most conserved bindingsubtypes and CRFs (%)
NC p1 p6 Gag
10.31 4.77 15.74 8.84
4.75 5.60 17.17 8.18
9.79 4.80 15.83 9.96
9.43 8.89 10.17 8.68
9.00 6.71 15.32 9.32
10.53 8.42 13.90 10.71
4.95 7.74 14.07 7.46
3.31 5.39 14.39 8.35
7.92±2.77 6.39±1.60 14.70±1.99 9.02±1.09
00.05
0.1
0.15
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Figure 2 (See legend on next page.)
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Figure 2 Amino acid conservation in HIV-1 full-length gag. (A) Density plots of CI values are shown for 8 HIV-1 subtypes. Secondary struc-
tures are indicated for each protein region, with thick lines for helices and thin lines for coiled-coil structures. Positions conserved in all subtypes
are colored blue (layer 1 in a small circle), known drug binding positions are colored red (layer 2) and regions where HIV-1 peptide inhibitors have
been derived are colored green (layer 3). (B) Distributions of CI values at 500 gag positions across 8 HIV-1 subtypes and CRFs. Visualization soft-
ware: Circos v0.64 (http://circos.ca/).
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http://www.retrovirology.com/content/10/1/126positions at the capsid N-terminal domain, with only
one being polymorphic (T107A/S, ≤ 6.2%) (Additional
file 1: Table S2).
Finally, we analyzed known crystal structures of 9
protein-inhibitor complexes, with 8 inhibitors targeting
a total of 75 positions (binding pockets 1–4) in capsid
and one targeting 23 positions in nucleocapsid (binding
pocket 5) (Figure 4, Additional file 2). Natural polymor-
phisms with prevalence ≥ 5% were observed in 28 posi-
tions of the binding pockets. Conserved positions were
observed in 56% of the capsid binding pockets and 43%
of the nucleocapsid binding pocket. Pocket 1 (0.0024)
had the lowest average CI values compared to pocket 2
(0.008), 3 (0.0216), 4 (0.0337) or 5 (0.0369).
Discussion and conclusions
To our knowledge, our large-scale analysis provided the
first detailed mapping of functional conservation of gag
across major HIV-1 subtypes, with implications for the ra-
tional design of gag inhibitors. With more than 50 gag in-
hibitors published to date, targeting virion morphogenesis
is considered a potential new drug class for HIV-1 treat-
ment [2]. A clinical proof-of-concept was demonstrated in
a phase II clinical trial of the maturation inhibitor bevirimat
[10], which blocks proteolytic processing at the capsid-p2
cleavage site [11]. Lack of response was observed in 50% of
patients and attributed to naturally occurring polymor-
phisms in the p2 region [8]. A single polymorphism V370A
is sufficient for a 40-fold reduction in bevirimat drug sus-
ceptibility [12], with A370 representing the consensus
amino acid in several non-B subtypes. Natural diversity was
also observed to affect drug effectiveness of other experi-
mental gag inhibitors [13-15]. Polymorphisms T190I,
E230D and I256V, for instance, reduced drug susceptibility
to the benzodiazepine and benzimidazole compounds [13].
Moreover, known HIV vaccine candidates containing sub-
type B gag gene in HIV-derived vectors did not show suffi-
cient protective efficacies in several large-scale clinical trials
[16]. The high diversity of gag and env genes within and be-
tween subtypes can contribute to the challenges of design-
ing a global HIV vaccine neutralizing all HIV-1 subtypes
[17]. For the development of HIV vaccine and a potential
new drug class targeting virion morphogenesis [2], an as-
sessment of gag functional conservation and polymor-
phisms at known drug binding positions is warranted.
We found that 23.4% of drug binding positions in the
full-length gag showed natural polymorphisms in non-Bsubtypes which could not be detected in subtype B.
More importantly, all gag inhibitors had at least one
polymorphic binding position irrespective of subtype.
We also found levels of gag intra- and inter-subtype di-
versity (9.04% and 17.0%) that exceeded diversity esti-
mates of key viral enzymes (< 7% and < 11%) targeted by
standard HIV-1 treatment [18]. However, the most con-
served gag protein capsid has the same level of intra-
subtype diversity as integrase (~5%) [18], favoring it as a
conserved drug target.
The capsid protein targeted by most candidate inhibi-
tors accounted for 67.7% of conserved gag positions
and contained 72.1% of the 136 binding positions previ-
ously reported. Our sequence analysis identified two
conserved capsid regions (Figure 2) located at the inter-
action interfaces between N-terminal domains (NTD-
NTD) as well as between N-terminal and C-terminal
domains (NTD-CTD) (Figure 5). These interaction
interfaces, crucial for the assembly and stabilization of
pentamer and hexamer lattices [19], provide potential
conserved drug targets. To reveal the ideal drug target,
we described 4 crystalized drug binding pockets in
capsid (Figure 4, Additional file 2: Figure S4). Inhibitors
that target pockets 1–3 have shown promising antiviral
activity against capsid multimerization in different subtype
strains by altering NTD-CTD interaction (pockets 1 and 3)
or NTD-NTD interaction (pocket 2) [15,20,21]. Pocket 4 is
less conserved and its polymorphic residues make direct
contact with inhibitors, hindering the development of in-
hibitors that target this pocket [13].
Another potential drug target is the nucleocapsid pro-
tein, containing two critical zinc-finger domains for
binding with viral RNA genomes [2]. Our conservation
analysis mapped the conserved nucleocapsid regions to
zinc-finger domains (Figures 2 and 5) and confirmed
previous findings of absolute conservation of CCHC mo-
tifs at zinc-coordinating positions [22]. However, we de-
tected considerable variation at other positions, which
may alter drug binding and affect antiviral activity. Fur-
thermore, nucleocapsid inhibitors tend to suffer from
limited specificity and high toxicity due to the ubiqui-
tous presence of zinc finger domains in many human
proteins [4].
Matrix inhibitors with broad spectrum antiviral activ-
ities were recently reported, but mutations at drug bind-
ing positions significantly reduced their effectiveness
[23,24]. We also observed many natural variants at their
Figure 3 Natural polymorphisms at 136 drug binding positions in 8 HIV-1 subtypes and CRFs. For each gag position, the HXB2 index is
shown at the top, followed by the consensus amino acid and natural polymorphisms. Polymorphisms with proportions ≥ 5% are indicated with
blue superscripts; orange otherwise.
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Figure 4 Mapping of drug binding positions and binding pockets to HIV-1 gag protein monomers. The surface spectrum colors indicate
the most to the least conserved positions in subtype B from blue CI = 0 to pink CI ≥ 0.1. (A) Secondary structures of 4 gag proteins and 2 spacer
peptides, annotated with five drug binding pocket locations. Gag proteins in cartoon representation are colored olive for matrix, blue for capsid, yellow
for nucleocapsid, grey for p6, gold for p1 and p2. Bound inhibitors are represented in green sticks. (B) Mapping of drug binding positions to a surface
representation of gag structure, with front and back views. Hypothesized binding positions of bevirimat are also annotated; known drug binding
positions are colored red. (C) Surface representation of gag conservation in HIV-1 subtype B (Figure S3 in Additional file 2 illustrates other subtypes). (D)
Surface representations of five drug binding pockets in HIV-1 subtype B (Figure S2 in Additional file 2 shows other subtypes). Inhibitor names are anno-
tated according to publication (Additional file 1: Table S1). PDB entries of gag proteins: matrix, 1HIW; capsid, 3NTE; p2, 1U57; nucleocapsid, 2M3Z; p6,
2C55. PDB data of capsid inhibitors: 2BUO, 2L6E, 2XDE, 4E91, 4E92, 2JPR and 4INB, each of which was superimposed to 3H4E using PDBs of 5 drug bind-
ing pockets: pocket 1, 2XDE; pocket 2, 4INB; pocket 3, 2BUO; pocket 4, 4E91; pocket 5, 2M3Z. PyMOL V1.5 (http://www.pymol.org/).
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ing that further optimization of matrix inhibitors is
needed.
Studies that analyzed genetic variability and drug bind-
ing site heterogeneity in gag using large-scale sequence
populations are lacking. Previously, small subtype B se-
quence datasets were used to characterize gag conserva-
tion (n = 125) [25] or positive selective pressure (n =
635) [26]. Polymorphisms at drug binding sites of capsid
inhibitor PF-3450074 [9] and conservation of nucleocap-
sid zinc-finger domains [22] were also reported using
fewer than 200 sequences. The only large-scale analysis
that we found [27] quantified the drug binding site con-
servation of a single matrix inhibitor and lacked infor-
mation on subtype-specific variations. By contrast, we
presented here a large-scale and integrative analysis
using 10862 full-length gag sequences, 136 gag inhibitor
drug binding positions and 14 PDB structures. Natural
polymorphisms of full-length gag were detected across 8
major HIV-1 subtypes and a robust estimation of func-
tional conservation was performed using CI analysis,
which incorporated biochemical similarities between
amino acids (Additional file 3). This sequence analysis
predicted three conserved drug targets in gag (Figure 2)
which were confirmed by existing structural knowledge
(Figure 5).
This study is limited in that it neither addressed how
to optimize known gag inhibitors nor quantified the im-
pact of newly identified polymorphisms on antiviral ac-
tivities of investigated inhibitors. We collected all
available PDBs of gag-inhibitor structures from the
RCSB protein data bank, but more crystallized com-
plexes are needed to reveal novel mechanisms of action.
Moreover, the limited number of available gag sequences
for subtypes F1, G and CRF02_AG (n < 100) may have
affected the identification of polymorphic positions, but
consistent conservation patterns were observed in gag
regardless of HIV-1 subtype (Figure 2). While we
attempted to be as comprehensive as possible, additional
inhibitors may have been reported. Conservation of their
binding positions can nevertheless be deduced from our
full-length gag analysis. Future studies are also needed
to address whether interactions between gag andprotease can affect gag drug binding sites, leading to
compromised drug activities of gag inhibitors [28].
In conclusion, our study presented a comprehensive
mapping of functional conservation in gag and strength-
ened the idea of capsid as a potential target for HIV-1
therapeutics. Increased knowledge on HIV-1 natural di-
versity in drug binding pockets contributes to rational
design of gag inhibitors and it remains a challenge to de-
sign gag inhibitors with drug binding sites conserved
across HIV-1 subtypes.
Methods
We retrieved 12543 gag sequences spanning all 1500
base pairs from the HIV Los Alamos database
(http://www.hiv.lanl.gov). Sequences were aligned against
the HXB2 reference and manually curated using Seaview
4.3 [29]. Hypermutated sequences were detected using
the Los Alamos hypermut tool [30]. HIV-1 subtype was
determined by the Rega [31] and COMET subtyping tools
(http://comet.retrovirology.lu/). Sequence quality was en-
sured by excluding duplicates and sequences with
internal stop-codons, hypermutations, more than 1% am-
biguous nucleotides, discordant subtype classification or
an identical combination of patient code, sampling year
and country. The analysis was restricted to the major
subtypes and circulating recombinant forms (CRFs) char-
acterizing the global HIV-1 subtype distribution [6]. For
each individual subtype, amino acids that differed from
the corresponding consensus AA and with prevalence ≥
0.5% were defined as polymorphisms [18]. PDB data of
protein-inhibitor complexes were collected from the RCSB
Protein Data Bank [32], summarized in Additional file 1.
The AA sequences in each PDB were aligned against the
HXB2 reference. Drug binding pockets were defined by
protein positions within a minimum Euclidean distance of
less than 5Å between atoms of inhibitors and non-
hydrogen atoms of residues [33]. Information on known
gag candidate inhibitors and binding positions was re-
trieved from more than 50 publications, summarized in
Additional file 1.
To quantify the degree of positional conservation, a
conservation index (CI) was calculated for each posi-
tion by averaging pairwise scores between all AAs
Figure 5 Visualization of conserved regions in capsid and nucleocapsid. The capsid hexamer structure (PDB: 3H4E) is shown in top (A) and
side (B) views, with the 6 capsid units (pink, blue), conserved NTD-NTD interaction domains (yellow) and conserved NTD-CTD interaction domains
(red). Figure (C) shows the structural complex of nucleocapsid and RNA (left, PDB: 1A1T) and the structural complex of nucleocapsid and inhibitor
CAA (right, PDB: 2M3Z). The first zinc-finger domain (nucleocapsid positions: 14–29, gag positions: 389–404) and the second zinc-finger domain
(nucleocapsid positions: 35–50, gag positions: 410–425) are colored red and orange, respectively. Figures S5 and S6 in Additional file 2 provide de-
tailed structures of conserved gag regions.
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from Karlin and Brocchieri [34], the conservation
index (CI) of position x is calculated as:
CI xð Þ ¼ 1− 2N N−1ð Þ
XN
i¼1
XN
j¼iþ1
S xi; xj
 
=
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
S xi; xið ÞS xj; xj
 q 
, where
xi is the amino acid at position x in the i
th sequence of
the multiple sequence alignment (MSA), N is the num-
ber of sequences in the MSA and S(xi, xj) is thesubstitution score of BLOSUM62 between amino acids
xi and xi. Given that denominators cannot be zero, a lin-
ear transformation was applied to S(xi, xj) by adding the
absolute value of the minimum score | min(S)| + 1. CI
measures were scaled between 0 and 1, with a CI value
of 0 indicating that AA variation was absent at that pos-
ition. A highly conserved position was identified if its CI
is below 0.01 for each HIV-1 subtype, a cutoff which
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rphism prevalence below 1% (Additional file 3). The
Mann–Whitney U test was performed to compare CI
distributions. Performance of the CI method is evaluated
in Additional file 3 and our Matlab toolbox for sequence
analysis is available in Additional file 4.
Additional files
Additional file 1: Table S1. The summary of gag candidate inhibitors
published in literature. Table S2. The prevalence of natural polymorphisms
at known drug binding sites in 8 HIV-1 subtypes and CFRs.
Additional file 2: Figure S1. The distribution of natural variations of
full-length gag in 8 HIV-1 subtypes. Figure S2. The surface representation
of full-length gag in 8 HIV-1 subtypes and CRFs. Figure S3. The surface
representation of five drug binding pockets in 8 HIV-1 subtypes. Figure S3.
The surface representation of full-length gag in 8 HIV-1 subtypes and CRFs.
Figure S4. The structure of capsid hexamer superimposed with 8 crystalized
inhibitors. Figure S5. The surface representation of conserved regions in
HIV-1 capsid Figure S6. The surface representation of conserved regions in
HIV-1 nucleocapsid.
Additional file 3: Note S1. The mathematical model of conservation
index. Note S2. The mathematical model of inter- and intra-subtype
diversity.
Additional file 4: The Matlab toolbox developed for conservation
analysis, inter- and intra-subtype diversity analysis. The full-length
gag sequence datasets are also included.
Abbreviations
AA: amino acid; CI: conservation index; CTD: C-terminal domain;
CRF: circulating recombinant form; MSA: multiple sequence alignment;
NC: nucleocapsid; NTD: N-terminal domain; PDB: protein data bank.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
GL and KT conceived and designed the study. All authors have participated
in the discussion and interpretation of the results and writing of the
manuscript. All authors read and approved the final manuscript.
Acknowledgements
We thank Supinya Piampongsant, Fossie Ferreira, Andrea Clemencia Pineda,
Ricardo Khouri, Mónica Eusébio, Soraya Maria Menezes and Dan Clements for
technical assistance and valuable contributions to the analysis. The research
leading to these results has been supported in part by the European
Community's Seventh Framework Programme (FP7/2007-2013) under the
project "Collaborative HIV and Anti-HIV Drug Resistance Network (CHAIN)"
grant agreement n° 223131; by the Fonds voor Wetenschappelijk Onderzoek
– Flanders (FWO) grant G.0611.09. GL acknowledged his funding from China
Scholarship Council. AV acknowledged his JSPS funding. KT received funding
from the Fonds voor Wetenschappelijk Onderzoek – Flanders (FWO).
Author details
1Rega Institute for Medical Research, Department of Microbiology and
Immunology, KU Leuven, Leuven, Belgium. 2Institute of Virology, University
hospital, University Duisburg-Essen, Essen, Germany. 3Division of Infectious
Diseases, Department of Medicine, Stanford University, Stanford, CA, USA.
4Zhang IRU, RIKEN Institute Laboratories, Hirosawa 2-1, Wako-shi, Saitama,
Japan. 5Centro de Malária e Outras Doenças Tropicais and Unidade de
Microbiologia, Instituto de Higiene e Medicina Tropical, Universidade Nova
de Lisboa, Lisbon, Portugal.
Received: 14 July 2013 Accepted: 21 October 2013
Published: 31 October 2013References
1. Engelman A, Cherepanov P: The structural biology of HIV-1: mechanistic
and therapeutic insights. Nat Rev Microbiol 2012, 10:279–290.
2. Waheed AA, Freed EO: HIV type 1 Gag as a target for antiviral therapy.
AIDS Res Hum Retroviruses 2012, 28:54–75.
3. Bocanegra R, Rodriguez-Huete A, Fuertes MA, Del Alamo M, Mateu MG:
Molecular recognition in the human immunodeficiency virus capsid and
antiviral design. Virus Res 2012, 169:388–410.
4. Dau B, Holodniy M: Novel targets for antiretroviral therapy: clinical
progress to date. Drugs 2009, 69:31–50.
5. Salzwedel K, Martin DE, Sakalian M: Maturation inhibitors: a new
therapeutic class targets the virus structure. AIDS Rev 2007, 9:162–172.
6. Hemelaar J, Gouws E, Ghys PD, Osmanov S: Isolation W-UNfH, Character-
isation: Global trends in molecular epidemiology of HIV-1 during 2000–
2007. AIDS 2011, 25:679–689.
7. Gaschen B, Taylor J, Yusim K, Foley B, Gao F, Lang D, Novitsky V, Haynes B,
Hahn BH, Bhattacharya T, Korber B: Diversity considerations in HIV-1 vac-
cine selection. Science 2002, 296:2354–2360.
8. Adamson CS, Sakalian M, Salzwedel K, Freed EO: Polymorphisms in Gag
spacer peptide 1 confer varying levels of resistance to the HIV- 1 matur-
ation inhibitor bevirimat. Retrovirology 2010, 7:36.
9. Blair WS, Pickford C, Irving SL, Brown DG, Anderson M, Bazin R, Cao J,
Ciaramella G, Isaacson J, Jackson L, et al: HIV capsid is a tractable target
for small molecule therapeutic intervention. PLoS Pathog 2010, 6:
e1001220.
10. Smith PF, Ogundele A, Forrest A, Wilton J, Salzwedel K, Doto J, Allaway GP,
Martin DE: Phase I and II study of the safety, virologic effect, and
pharmacokinetics/pharmacodynamics of single-dose 3-o-(3',3'-dimethyl-
succinyl)betulinic acid (bevirimat) against human immunodeficiency
virus infection. Antimicrob Agents Chemother 2007, 51:3574–3581.
11. Nguyen AT, Feasley CL, Jackson KW, Nitz TJ, Salzwedel K, Air GM, Sakalian M:
The prototype HIV-1 maturation inhibitor, bevirimat, binds to the CA-SP1
cleavage site in immature Gag particles. Retrovirology 2011, 8:101.
12. Lu W, Salzwedel K, Wang D, Chakravarty S, Freed EO, Wild CT, Li F: A single
polymorphism in HIV-1 subtype C SP1 is sufficient to confer natural re-
sistance to the maturation inhibitor bevirimat. Antimicrob Agents
Chemother 2011, 55:3324–3329.
13. Goudreau N, Lemke CT, Faucher AM, Grand-Maitre C, Goulet S, Lacoste JE,
Rancourt J, Malenfant E, Mercier JF, Titolo S, Mason SW: Novel inhibitor
binding site discovery on HIV-1 capsid N-terminal domain by NMR and
X-ray crystallography. ACS Chem Biol 2013.
14. Bartonova V, Igonet S, Sticht J, Glass B, Habermann A, Vaney MC, Sehr P,
Lewis J, Rey FA, Krausslich HG: Residues in the HIV-1 capsid assembly
inhibitor binding site are essential for maintaining the assembly-
competent quaternary structure of the capsid protein. J Biol Chem 2008,
283:32024–32033.
15. Lemke CT, Titolo S, von Schwedler U, Goudreau N, Mercier JF, Wardrop E,
Faucher AM, Coulombe R, Banik SS, Fader L, et al: Distinct effects of two
HIV-1 capsid assembly inhibitor families that bind the same site within
the N-terminal domain of the viral CA protein. J Virol 2012, 86:6643–6655.
16. Schiffner T, Sattentau QJ, Dorrell L: Development of prophylactic vaccines
against HIV-1. Retrovirology 2013, 10:72.
17. Stephenson KE, Barouch DH: A global approach to HIV-1 vaccine develop-
ment. Immunol Rev 2013, 254:295–304.
18. Rhee SY, Liu TF, Kiuchi M, Zioni R, Gifford RJ, Holmes SP, Shafer RW: Natural
variation of HIV-1 group M integrase: implications for a new class of anti-
retroviral inhibitors. Retrovirology 2008, 5:74.
19. Yufenyuy EL, Aiken C: The NTD-CTD intersubunit interface plays a critical
role in assembly and stabilization of the HIV-1 capsid. Retrovirology 2013,
10:29.
20. Zhang H, Curreli F, Zhang X, Bhattacharya S, Waheed AA, Cooper A,
Cowburn D, Freed EO, Debnath AK: Antiviral activity of alpha-helical sta-
pled peptides designed from the HIV-1 capsid dimerization domain.
Retrovirology 2011, 8:28.
21. Goudreau N, Coulombe R, Faucher AM, Grand-Maitre C, Lacoste JE, Lemke CT,
Malenfant E, Bousquet Y, Fader L, Simoneau B, et al:Monitoring binding of HIV-1
capsid assembly inhibitors using (19)F ligand-and (15)N protein-based NMR
and X-ray crystallography: early hit validation of a benzodiazepine series.
ChemMedChem 2013, 8:405–414.
22. Thomas JA, Gorelick RJ: Nucleocapsid protein function in early infection
processes. Virus Res 2008, 134:39–63.
Li et al. Retrovirology 2013, 10:126 Page 11 of 11
http://www.retrovirology.com/content/10/1/12623. Zentner I, Sierra LJ, Fraser AK, Maciunas L, Mankowski MK, Vinnik A,
Fedichev P, Ptak RG, Martin-Garcia J, Cocklin S: Identification of a
small-molecule inhibitor of HIV-1 assembly that targets the
phosphatidylinositol (4,5)-bisphosphate binding site of the HIV-1 matrix
protein. ChemMedChem 2013, 8:426–432.
24. Alfadhli A, McNett H, Eccles J, Tsagli S, Noviello C, Sloan R, Lopez CS, Peyton
DH, Barklis E: Analysis of small molecule ligands targeting the HIV-1
matrix protein-RNA binding site. J Biol Chem 2013, 288:666–676.
25. Frahm N, Kaufmann DE, Yusim K, Muldoon M, Kesmir C, Linde CH, Fischer
W, Allen TM, Li B, McMahon BH, et al: Increased sequence diversity
coverage improves detection of HIV-specific T cell responses. J Immunol
2007, 179:6638–6650.
26. Snoeck J, Fellay J, Bartha I, Douek DC, Telenti A: Mapping of positive
selection sites in the HIV-1 genome in the context of RNA and protein
structural constraints. Retrovirology 2011, 8:87.
27. Zentner I, Sierra LJ, Maciunas L, Vinnik A, Fedichev P, Mankowski MK, Ptak RG,
Martin-Garcia J, Cocklin S: Discovery of a small-molecule antiviral targeting
the HIV-1 matrix protein. Bioorg Med Chem Lett 2013, 23:1132–1135.
28. Fun A, Wensing AM, Verheyen J, Nijhuis M: Human immunodeficiency
virus Gag and protease: partners in resistance. Retrovirology 2012, 9:63.
29. Gouy M, Guindon S, Gascuel O: SeaView version 4: A multiplatform
graphical user interface for sequence alignment and phylogenetic tree
building. Mol Biol Evol 2010, 27:221–224.
30. Rose PP, Korber BT: Detecting hypermutations in viral sequences with an
emphasis on G –> A hypermutation. Bioinformatics 2000, 16:400–401.
31. Pineda-Pena AC, Faria NR, Imbrechts S, Libin P, Abecasis AB, Deforche K,
Gomez-Lopez A, Camacho RJ, de Oliveira T, Vandamme AM: Automated
subtyping of HIV-1 genetic sequences for clinical and surveillance pur-
poses: Performance evaluation of the new REGA version 3 and seven
other tools. Infect Genet Evol 2013.
32. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H,
Shindyalov IN, Bourne PE: The protein data bank. Nucleic Acids Res 2000,
28:235–242.
33. Zhang Z, Li Y, Lin B, Schroeder M, Huang B: Identification of cavities on
protein surface using multiple computational approaches for drug
binding site prediction. Bioinformatics 2011, 27:2083–2088.
34. Brocchieri L, Karlin S: Conservation among HSP60 sequences in relation to
structure, function, and evolution. Protein Sci 2000, 9:476–486.
doi:10.1186/1742-4690-10-126
Cite this article as: Li et al.: Functional conservation of HIV-1 gag:
implications for rational drug design. Retrovirology 2013 10:126.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
